HanchorBio (TPE:7827) Other Stockholders Equity: NT$-107.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:7827 HanchorBio Inc TPE:7827
9 GF Score
Price NT$156.00
View Full Analysis

What is HanchorBio Other Stockholders Equity?

HanchorBio TPE:7827 -0.32% 9 Other Stockholders Equity is NT$-107.0 Mil as of Mar. 2026. GuruFocus rates TPE:7827 with a GF Score™ of 9/100.

HanchorBio's Other Stockholders Equity for the quarter that ended in Mar. 2026 was NT$-107.0 Mil.

HanchorBio's quarterly Other Stockholders Equity increased from Sep. 2025 (NT$-135.9 Mil) to Dec. 2025 (NT$-115.5 Mil) and increased from Dec. 2025 (NT$-115.5 Mil) to Mar. 2026 (NT$-107.0 Mil).

HanchorBio's annual Other Stockholders Equity declined from Dec. 2023 (NT$-47.7 Mil) to Dec. 2024 (NT$-129.9 Mil) but then increased from Dec. 2024 (NT$-129.9 Mil) to Dec. 2025 (NT$-115.5 Mil).

HanchorBio Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for HanchorBio's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HanchorBio Other Stockholders Equity Chart

HanchorBio Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
-50.07 -47.72 -129.89 -115.52

HanchorBio Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only 0.00 -130.90 -135.89 -115.52 -106.96
TPE:7827
9GF Score
HanchorBio Inc TPE:7827
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HanchorBio Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$-107.0 Mil mean?
HanchorBio (TPE:7827) has a Other Stockholders Equity of NT$-107.0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HanchorBio and its competitors.
Is HanchorBio's Other Stockholders Equity too high?
HanchorBio's current Other Stockholders Equity is NT$-107.0 Mil. Overall, HanchorBio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HanchorBio's Other Stockholders Equity compare to VRTX and REGN?
HanchorBio's Other Stockholders Equity of NT$-107.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on HanchorBio and its competitors. HanchorBio's current Other Stockholders Equity is NT$-107.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HanchorBio stock overvalued right now?
HanchorBio (TPE:7827) has a current Other Stockholders Equity of NT$-107.0 Mil. The current Other Stockholders Equity is NT$-107.0 Mil. HanchorBio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For HanchorBio (TPE:7827), the current Other Stockholders Equity is NT$-107.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HanchorBio Business Description

Address Sector 1, Tiding Boulevard, 5th Floor, No. 1, Neihu District, Taipei, TWN, 114
HanchorBio Inc through its subsidiaries, is conducting research and development of new anti-cancer drugs, utilizing an Fc-based biopharmaceutical platform technology to reactivate the immune system in the fight against disease. The core technology of HanchorBio is the FBDB (Fc-Based Designer Biologics) platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutics. This platform utilizes the antibody Fc region as a backbone, onto which various engineered anti-cancer molecules are constructed through protein engineering. Combined with AI-assisted drug design capabilities, this technology is dedicated to overcoming key challenges in tumor immunotherapy.
9GF Score

Get the complete analysis for TPE:7827

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$156.00
Price